Yelisa Rivero

Onychomycosis

Based on the patient’s condition, after therapy, she will be referred to a podiatrist because the patient needs to be monitored and some follow-up treatment. The reason for monitoring and caring services by a podiatrist is because of the patient’s diabetic condition. She has type 2 diabetes, which would apply to any diabetic patient with the same condition (Snell et al., 2016). However, diabetes-related treatment is not accounted for; this also, it important for the patient to seek further medication based on observation like her obese condition, which is a sign of an improper diet.  Based on the recommended guidelines, one of the non-pharmacological means of addressing onychomycosis is using the Vicks VapoRub ointment. That is based on test studies carried out on the ointment on its level of effectiveness in addressing the infection. As a non-pharmacological approach, the tests were encouraging since the drug effectiveness tests were positive. Additionally, despite the proven effectiveness, as a non-pharmacological approach, the ointment is safe and cost-effective, making it the most suitable alternative to pharmacological treatment of onychomycosis.

Concerning the patient’s past medical history, the patient needs to be enlightened about healthy dietary practices. Since she is obese, the patient needs to adhere to a healthy diet with minimal cholesterol and more fruits and vegetables. The discovery of low HDL calls for more uptake of fatty acids. Additionally, the patient must adhere to an active lifestyle that includes regular physical exercise as a control measure for the obese condition. 

Reference

Snell, M., Klebert, M., Önen, N. F., & Hubert, S. (2016). A novel treatment for onychomycosis in people living with HIV infection: Vicks VapoRub™ is effective and safe. Journal of the Association of Nurses in AIDS Care, 27(1), 109-113. DOI: 10.1016/j.jana.2015.10.004

Elsa Sosa

February 5, 2021-related fungal infections are one of the most common infections experienced by

human beings. Onychomycosis is one of the fungal infections that is found in both fingernails

and toenails. Three main medications can be used to treat a patient suffering from

onychomycosis. Ciclopirox is the first topical treatment that should be prescribed for a patient

suffering from onychomycosis. The solution was approved for treatment by the FDA back in

1999. It is mainly used to treat mild to moderate onychomycosis. Ciclopirox inhibits fungal

growth. However, the drug requires trimming and filling the affected nail. For maximum results,

the solution should be applied once every day for about 48 weeks when dealing with a toenail.

Efinaconazole, 10% solution, is the second-best medication to prescribe to a patient suffering

from onychomycosis. The solution works by disrupting the fungal cell membrane and also

inhibits 14 alpha-demethylase. It should also be applied once per day for 48 weeks. However, it

should be used on the entire nail plate and also the undersurface of the nail plate (Gupta et al.,

2005).

When dealing with onychomycosis, it is imperative to do some routine baseline testing as

a precaution. Baseline labs and a lab check should be conducted at least six weeks after the

medication has started. I would recommend using three lab tests for a patient with

onychomycosis: microscopic examination, mycologic culture, and PAS stain. Results from the

three two tests will shed a lot of light on whether there is a contaminant present and if it’s a

legitimate infection. The microscopic examination will be essential in determining where the

fungus is mainly located, either within the parenchyma or the nail plate. After that, it will easy to

determine if the medication prescribed is working. A mycologic culture will be beneficial in

determining whether the fungi strain is alive or dead. The three tests will provide information

that could be essential in preventing the condition from getting worse (Robert et al., 2003)

Gupta, A. K., Schouten, J. R., & Lynch, L. E. (2005). Ciclopirox nail lacquer 8% for the

treatment of onychomycosis: a Canadian perspective. Skin therapy letter, 10(7),

1-3.

Roberts, D. T., Taylor, W. D., & Boyle, J. (2003). Guidelines for treatment of

onychomycosis. British Journal of Dermatology, 148(3), 402-410.

PLACE THIS ORDER OR A SIMILAR ORDER WITH Nursing League TODAY AND GET AN AMAZING DISCOUNT